Pharmaceutical Industry Payments and Oncologists’ Selection of Targeted Cancer Therapies in Medicare Beneficiaries | Zendy

Aaron P. Mitchell | Zendy; Aaron N. Winn | Zendy; Stacie B. Dusetzina | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmaceutical Industry Payments and Oncologists’ Selection of Targeted Cancer Therapies in Medicare Beneficiaries

Author(s) -

Aaron P. Mitchell,

Aaron N. Winn,

Stacie B. Dusetzina

Publication year - 2018

Publication title -

jama internal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.14

H-Index - 342

eISSN - 2168-6114

pISSN - 2168-6106

DOI - 10.1001/jamainternmed.2018.0776

Subject(s) - medicine , medicaid , asthma , exacerbation , corticosteroid , copd , pneumonia , lung cancer , diabetes mellitus , adverse effect , intensive care medicine , health care , economics , endocrinology , economic growth

Pharmaceutical Industry Payments and Oncologists’ Selection of Targeted Cancer Therapies in Medicare Beneficiaries Physicians and teaching hospitals in the United States receive approximately $7 billion from the pharmaceutical industry annually.1 These payments have been associated with higher-cost, brand-name pharmaceutical prescribing.2-4 Whether industry payments are associated with physician treatment choice in oncology is uncertain. We examined the association between oncologists’ receipt of payments from pharmaceutical manufacturers and drug selection in 2 situations where there are multiple treatment options.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research